Is Compounded Semaglutide Safe, Legal and the Same as Ozempic?

• Safe? Compounded versions skip FDA review for safety, effectiveness and quality. The FDA has documented dosing errors from multi-dose vials, doses beyond the approved label, products that arrived warm, and fraudulent labels naming pharmacies that never made the drug.
• Legal? The FDA declared the tirzepatide shortage resolved (Oct 2, 2024, reaffirmed Dec 19, 2024) and the semaglutide shortage resolved (Feb 21, 2025). Pharmacies may still compound for an individual prescription, but not regular copies of an approved drug unless a prescriber documents a significant difference for that patient.
• Same as Ozempic? No. The FDA lists “claims that the compounded drug is the same as an FDA-approved drug” as a red flag, and warned Hers (Sep 2025) and 30 telehealth companies (Mar 2026) over sameness claims. Salt forms (semaglutide sodium or acetate) have no lawful basis in compounding, per the FDA.
• Cheapest FDA-approved alternative: the Wegovy pill and Foundayo start at $149 a month self-pay; Wegovy pens are $349 after two $199 starter fills (checked Oct 11, 2026).

Partner links may earn us a commission. Learn more

Sorted by the lowest published monthly cost. "Starting at" prices can change after a clinician sets your dose. Linked brands are affiliate or applied-for programs (rel="sponsored"); other sellers are listed as plain text for price context only.

The FDA does not review compounded drugs for safety, effectiveness or quality before they are sold, so the brand-name trial results do not automatically apply. It says compounded drugs should be used only when a patient’s medical need cannot be met by an FDA-approved drug.

Specific problems the FDA reports: patients and prescribers miscalculating doses when converting mg to syringe units (some patients took 5 to 20 times the intended dose); doses and titration faster than the approved labels; injectables that arrived warm; fraudulent products whose labels name pharmacies that do not exist or did not make them; and, as of May 31, 2026, 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide. State-licensed pharmacies do not have to report adverse events to the FDA, so these are likely undercounts.

While semaglutide and tirzepatide were on the FDA shortage list, compounders had wide latitude to copy them. The FDA declared the tirzepatide shortage resolved on October 2, 2024 (reaffirmed December 19, 2024) and the semaglutide shortage resolved on February 21, 2025. Its grace periods ended for state-licensed pharmacies on March 5, 2025 (tirzepatide) and April 24, 2025 (semaglutide), after court rulings, and for outsourcing facilities on March 19 and May 22, 2025.

As of April 1, 2026, a state-licensed (503A) pharmacy may still compound for an individual prescription, but may not compound essentially a copy of a commercially available drug regularly or in inordinate amounts unless the prescriber documents a significant difference for that patient. The FDA says it does not intend to act against a pharmacy that fills four or fewer such prescriptions in a calendar month, and gives semaglutide plus vitamin B12 at strengths within 10% of approved products as an example of what may still count as a copy. Outsourcing (503B) facilities cannot use semaglutide or tirzepatide bulk ingredient at all while neither is on the shortage or bulks list.

• No. Ozempic and Wegovy are FDA-approved semaglutide made by Novo Nordisk; Zepbound and Mounjaro are FDA-approved tirzepatide made by Eli Lilly. A compounded product is a pharmacy preparation that was never tested in their trials.
• Some compounders have used semaglutide sodium or semaglutide acetate, which the FDA says are different active ingredients with no known lawful basis for compounding.
• On September 9, 2025 the FDA told Hims & Hers that website claims for its compounded semaglutide, including “same active ingredient as Ozempic and Wegovy,” were false or misleading. On March 3, 2026 it announced 30 more warning letters to telehealth companies over similar claims, noting that compounded drugs are also not FDA-approved generics.

• The seller claims its compounded drug is the same as an FDA-approved drug.
• Deep discounts or prices that seem too good to be true.
• Medicine that looks different than expected, damaged packaging, or no instructions.
• No screening and prescription by a licensed clinician, or no clinician to answer questions later.
• Spelling errors or wrong pharmacy addresses on the label.
• Anything sold “for research purposes” or “not for human consumption.”

Prices and product facts come from each seller’s own pages, read Oct 11, 2026. We link only to sellers we have an affiliate relationship with and to government and research sources; other sellers' prices are quoted as plain text.

• FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of Oct 1, 2026)
• FDA: Clarifies policies for compounders as national GLP-1 supply begins to stabilize (content current as of Apr 1, 2026)
• FDA: Dosing errors associated with compounded injectable semaglutide
• FDA warning letter to Hims & Hers Health, Inc. dba Hers (Sep 9, 2025)
• FDA: Warns 30 telehealth companies against illegal marketing of compounded GLP-1s (Mar 3, 2026)

Also read for prices (not linked; no affiliate relationship): novocare.com, lilly.com.